Galapagos NV
26.02
24-12月-24 06:54:02
15 分の遅延
株式
+0.22
+0.85%
本日の幅
25.85 - 26.16
ISIN
BE0003818359
ソース
Cboe
-
Galapagos appoints Paul Stoffels as Chief Executive Officer
26 1 2022 15:01:00 提供 Nasdaq GlobeNewswire
-
18 1 2022 15:01:00 提供 Nasdaq GlobeNewswire
-
Galapagos creates new subscription right plan
13 1 2022 15:01:00 提供 Nasdaq GlobeNewswire
-
Galapagos to present at 40th Annual J.P. Morgan Healthcare Conference
06 1 2022 08:30:00 提供 Nasdaq GlobeNewswire
-
Galapagos increases share capital through subscription right exercises
03 12 2021 15:01:00 提供 Nasdaq GlobeNewswire
-
22 11 2021 15:01:00 提供 Nasdaq GlobeNewswire
-
Jyseleca®▼(filgotinib) approved in the European Union for the treatment of ulcerative colitis
15 11 2021 09:45:07 提供 Nasdaq GlobeNewswire
-
Galapagos reports commercial and operational progress at Q3 financial results
04 11 2021 16:01:00 提供 Nasdaq GlobeNewswire
-
04 10 2021 15:01:00 提供 Nasdaq GlobeNewswire
-
04 10 2021 00:01:00 提供 Nasdaq GlobeNewswire
-
Galapagos increases share capital through subscription right exercises
20 9 2021 15:01:00 提供 Nasdaq GlobeNewswire
-
17 9 2021 06:15:00 提供 Nasdaq GlobeNewswire
-
Galapagos announces planned retirement of CEO
30 8 2021 15:01:00 提供 Nasdaq GlobeNewswire
-
Galapagos reports H1 financial results with refocused pipeline and operational progress
05 8 2021 15:01:00 提供 Nasdaq GlobeNewswire
-
Galapagos demonstrates early clinical activity with SIK2/3 inhibition in inflammation
14 7 2021 15:01:00 提供 Nasdaq GlobeNewswire
-
14 7 2021 15:01:00 提供 Nasdaq GlobeNewswire
-
10 7 2021 04:10:00 提供 Nasdaq GlobeNewswire
-
Galapagos announces departure of CSO Piet Wigerinck later this year
22 6 2021 15:01:00 提供 Nasdaq GlobeNewswire
-
Galapagos increases share capital through subscription right exercises
07 6 2021 15:01:00 提供 Nasdaq GlobeNewswire
-
SELECTION study on filgotinib in ulcerative colitis published in The Lancet
04 6 2021 00:01:00 提供 Nasdaq GlobeNewswire